reduce: Delirium in critically ill ICU patients dataset: the REDUCE...

reduceR Documentation

Delirium in critically ill ICU patients dataset: the REDUCE clinical trial

Description

This dataset contains an extract of 500 randomly selected patients from the randomized, double-blind, placebo-controlled REDUCE trial for critically ill patient admited to ICU. This trial investigated whether Haloperidol (1 or 2 mg) administered as a prophylactic improved 28-day survival compared to placebo. Recurrent episodes of delirium are recorded and patients and patients can be censored by death or discharge from the ICU.

Usage

data(reduce)

Format

This data frame contains the following columns:

id

Identification number of a patient

t.start

Start time of the interval (0 or time of last recurrence)

t.stop

Stop time of the interval, either delirium recurrence time or censoring time.

del

Delirium status

death

Death status

discharge

Discharge status

treatment

Treatment indicator, 1 if patient was randomized to receive 2mg of Haloperidol, 0 for control

Source

Van Den Boogaard, M., Slooter, A. J., Bruggemann, R. J., Schoonhoven, L., Beishuizen, A., Vermeijden, J. W., et al. (2018). Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial. Jama, 319(7), 680-690.


frailtypack documentation built on Oct. 20, 2024, 1:08 a.m.